NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$15.95 USD
-0.48 (-2.92%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $15.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Cash flow Statements
Fiscal Year End for NovoCure Limited falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -207.04 | -92.53 | -58.35 | 19.81 | -7.23 |
Depreciation/Amortization & Depletion | -12.12 | 9.09 | 13.35 | 12.41 | 6.28 |
Net Change from Assets/Liabilities | 29.66 | 11.80 | 29.07 | -8.52 | -24.33 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 116.17 | 102.44 | 98.69 | 75.45 | 51.90 |
Net Cash From Operating Activities | -73.34 | 30.79 | 82.76 | 99.15 | 26.62 |
Property & Equipment | -27.09 | -21.36 | -24.17 | -14.97 | -10.49 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 211.24 | -118.60 | -120.66 | -457.88 | -41.18 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 184.15 | -139.96 | -144.83 | -472.85 | -51.67 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 15.80 | 15.52 | 25.73 | 31.80 | 61.71 |
Issuance (Repayment) of Debt | -0.01 | -0.03 | -0.03 | 408.41 | -0.03 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 15.79 | 15.49 | 25.70 | 440.21 | 61.68 |
Effect of Exchange Rate Changes | 0.13 | -0.10 | -0.19 | 0.25 | 0.03 |
Net Change In Cash & Equivalents | 126.73 | -93.78 | -36.56 | 66.76 | 36.66 |
Cash at Beginning of Period | 115.83 | 209.61 | 246.17 | 179.42 | 142.76 |
Cash at End of Period | 242.56 | 115.83 | 209.61 | 246.17 | 179.42 |
Diluted Net EPS | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 |
Fiscal Year End for NovoCure Limited falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -72.14 | -38.76 | -207.04 | -159.96 | -110.48 |
Depreciation/Amortization & Depletion | -6.56 | -2.57 | -12.12 | -7.58 | -3.69 |
Net Change from Assets/Liabilities | -23.38 | -26.76 | 29.66 | 7.50 | 1.78 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 68.79 | 36.51 | 116.17 | 101.26 | 72.92 |
Net Cash From Operating Activities | -33.29 | -31.57 | -73.34 | -58.78 | -39.46 |
Property & Equipment | -23.23 | -11.78 | -27.09 | -20.27 | -13.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -104.99 | 258.00 | 211.24 | 105.92 | 81.41 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -128.22 | 246.22 | 184.15 | 85.65 | 68.39 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.52 | 0.21 | 15.80 | 13.89 | 12.72 |
Issuance (Repayment) of Debt | 84.01 | 0.00 | -0.01 | -0.01 | -0.01 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 87.53 | 0.21 | 15.79 | 13.88 | 12.71 |
Effect of Exchange Rate Changes | -0.13 | -0.06 | 0.13 | -0.07 | 0.03 |
Net Change In Cash & Equivalents | -74.12 | 214.80 | 126.73 | 40.68 | 41.66 |
Cash at Beginning of Period | 242.56 | 242.56 | 115.83 | 115.83 | 115.83 |
Cash at End of Period | 168.44 | 457.36 | 242.56 | 156.51 | 157.49 |
Diluted Net EPS | -0.31 | -0.36 | -0.45 | -0.46 | -0.54 |